Compare Amgen, Inc. (AMGN) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Matson Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Matson Inc trades at $204.77 (market cap $6.20B). The key difference: Amgen, Inc. is far larger — about 31.6× Matson Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MATX | |
|---|---|---|
Market Cap | $196.12B | $6.20B |
Sector | Health | Technology |
52-Week High | $388.16 | $206.03 |
52-Week Low | $271.18 | $88.05 |
Enterprise Value | $241.41B | $6.79B |
Dividend Yield | 2.77% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Matson (MATX) trades at $204.77, down 0.61% today but near recent highs, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.85 exceeding expectations. Fundamentals show solid profitability with a 12.92% net income margin and a reasonable P/E of 15.19. Recent developments include a dividend increase to $0.38 per share and progress on new vessel construction.
The outlook remains positive given consistent earnings outperformance and strategic fleet investments, though risks include exposure to Pacific trade volatility and moderating profit margins. Analyst consensus is bullish with 64% buy ratings, supporting potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
